Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina.
Docosahexaenoic acid (22:6, n-3), a major component of retinal phospholipids, is a substrate for active lipoxygenation in intact canine retinas incubated in vitro with [U-14C]docosahexaenoic acid. The major lipoxygenase reaction product was identified by high performance liquid chromatography and gas chromatography-mass spectrometry as 11-hydroxy-4,7,9-(trans)13,16,19 docosahexaenoic acid. Other mono- and di-hydroxy derivatives also were detected. The synthesis of these compounds was inhibited by the antioxidant and lipoxygenase inhibitor, nordihydroguaiaretic acid, but was not inhibited by indomethacin or esculetin.
D000818:Animals; D002250:Carbon Radioisotopes; D002396:Catechols / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D004281:Docosahexaenoic Acids; D004285:Dogs; D005231:Fatty Acids, Unsaturated / Q000378:metabolism*; D007213:Indomethacin / Q000494:pharmacology; D008084:Lipoxygenase / Q000378:metabolism*; D009637:Masoprocol; D013058:Mass Spectrometry; D012160:Retina / Q000187:drug effects / Q000378:metabolism*; D014468:Umbelliferones / Q000494:pharmacology
D002250:Carbon Radioisotopes; D002396:Catechols; D005231:Fatty Acids, Unsaturated; D014468:Umbelliferones; D004281:Docosahexaenoic Acids; D009637:Masoprocol; D008084:Lipoxygenase; C007628:esculetin; D007213:Indomethacin